drugset / Trial / NCT07560865
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Phase 1
Recruiting
9 enrolled
Masonic Cancer Center, University of Minnesota
Fate Therapeutics · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single center, first-in cancer-type phase I clinical trial of FT536 for adult patients with recurrent WHO Grade 4 astrocytoma, irrespective of IDH-mutational status, for which a standard of care repeat craniotomy for gross tumor resection at time of first or second recurrence is achievable. Per this treatment schema, FT536 will be administered once intratumorally
Timeline
- Start
- 2026-04-23
- Primary completion
- 2028-06-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT536 | Cell therapy | 1e+07 cells | Intrathecal |
| Subject | FT536 | Cell therapy | 2e+07 cells | Intrathecal |
| Subject | FT536 | Cell therapy | 6e+07 cells | Intrathecal |